These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30153998)

  • 1. PD-L1 expression in meningiomas.
    Johnson MD
    J Clin Neurosci; 2018 Nov; 57():149-151. PubMed ID: 30153998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma.
    Han SJ; Reis G; Kohanbash G; Shrivastav S; Magill ST; Molinaro AM; McDermott MW; Theodosopoulos PV; Aghi MK; Berger MS; Butowski NA; Barani I; Phillips JJ; Perry A; Okada H
    J Neurooncol; 2016 Dec; 130(3):543-552. PubMed ID: 27624915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of the status of immune checkpoint molecules (PD-L1 and PD-1) in meningiomas by immunohistochemistry.
    Saygin İ; Çakir E; Kazaz SN; Güvercin AR; Eyüpoğlu İ; Ustaoğlu MM
    Turk J Med Sci; 2024; 54(4):735-743. PubMed ID: 39295608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic and local immunosuppression in patients with high-grade meningiomas.
    Li YD; Veliceasa D; Lamano JB; Lamano JB; Kaur G; Biyashev D; Horbinski CM; Kruser TJ; Bloch O
    Cancer Immunol Immunother; 2019 Jun; 68(6):999-1009. PubMed ID: 31030234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
    Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
    J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 regulates tumor proliferation and T-cell function in NF2-associated meningiomas.
    Wang Y; Zhang C; Yan M; Ma X; Song L; Wang B; Li P; Liu P
    CNS Neurosci Ther; 2024 Jun; 30(6):e14784. PubMed ID: 38828669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.
    Du Z; Abedalthagafi M; Aizer AA; McHenry AR; Sun HH; Bray MA; Viramontes O; Machaidze R; Brastianos PK; Reardon DA; Dunn IF; Freeman GJ; Ligon KL; Carpenter AE; Alexander BM; Agar NY; Rodig SJ; Bradshaw EM; Santagata S
    Oncotarget; 2015 Mar; 6(7):4704-16. PubMed ID: 25609200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas.
    Yeung J; Yaghoobi V; Aung TN; Vesely MD; Zhang T; Gaule P; Gunel M; Rimm DL; Chen L
    J Neuropathol Exp Neurol; 2021 Jan; 80(2):150-159. PubMed ID: 33393633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.
    Deng J; Ma M; Wang D; Zhu H; Hua L; Sun S; Chen H; Cheng H; Qian ZR; Xie Q; Zhang T; Gong Y
    World Neurosurg; 2020 Mar; 135():e12-e18. PubMed ID: 31629137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Na-K-2Cl cotransporter and aquaporin 1 in arachnoid granulations, meningiomas, and meningiomas invading dura.
    Johnson MD; O'Connell M
    Hum Pathol; 2013 Jun; 44(6):1118-24. PubMed ID: 23317544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunocytochemical analysis of glucose transporter protein-1 (GLUT-1) in typical, brain invasive, atypical and anaplastic meningioma.
    van de Nes JA; Griewank KG; Schmid KW; Grabellus F
    Neuropathology; 2015 Feb; 35(1):24-36. PubMed ID: 25168354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression.
    Karimi S; Mansouri S; Mamatjan Y; Liu J; Nassiri F; Suppiah S; Singh O; Aldape K; Zadeh G
    Sci Rep; 2020 Aug; 10(1):14115. PubMed ID: 32839486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.
    Everson RG; Hashimoto Y; Freeman JL; Hodges TR; Huse J; Zhou S; Xiu J; Spetzler D; Sanai N; Kim L; Kesari S; Brenner A; De Monte F; Heimberger A; Raza SM
    J Neurooncol; 2018 Sep; 139(2):469-478. PubMed ID: 29846894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
    Ozen O; Demirhan B; Altinörs N
    Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status.
    Karimi S; Mansouri S; Nassiri F; Bunda S; Singh O; Brastianos PK; Dunn IF; Zadeh G
    J Neurooncol; 2021 Feb; 151(3):443-449. PubMed ID: 33611710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
    Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
    Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.
    Giles AJ; Hao S; Padget M; Song H; Zhang W; Lynes J; Sanchez V; Liu Y; Jung J; Cao X; Fujii R; Jensen R; Gillespie D; Schlom J; Gilbert MR; Nduom EK; Yang C; Lee JH; Soon-Shiong P; Hodge JW; Park DM
    JCI Insight; 2019 Oct; 4(20):. PubMed ID: 31536478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
    Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
    Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
    Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
    APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: an immunohistochemical and fluorescence in situ hybridization pilot study.
    Caltabiano R; Barbagallo GM; Castaing M; Cassenti A; Senetta R; Cassoni P; Albanese V; Lanzafame S
    J Neurosurg Sci; 2013 Jun; 57(2):139-51. PubMed ID: 23486338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.